Amino Acid, Peptide, or Protein – Page 50

Milestone’s Etripamil Nasal Spray Advances Towards Regulatory Filing in China for PSVT Treatment

8 months ago talkbio0Tagged Cardiovascular system, China, etripamil nasal spray, Milestone, Paroxysmal, Paroxysmal supraventricular tachycardia, Pharmaceuticals Ltd, Regulatory Filing, Tenascin, human

Etripamil nasal spray, Paroxysmal supraventricular tachycardia (PSVT), Milestone Pharmaceuticals, Ji Xing Pharmaceuticals Ltd, China regulatory filing, Cardiovascular therapies

GSK’s Nucala Demonstrates Efficacy in COPD with Positive Phase III Trial Results

8 months ago talkbio0Tagged Asthma, Chronic Obstructive Airway Disease, interleukin-5, mepolizumab, Monoclonal Antibodies, Nucala, Phase 3 Clinical Trials, SmithKline Beecham

GSK, Nucala, COPD, Phase III trial, mepolizumab, chronic obstructive pulmonary disease, asthma, IL-5 antagonist, monoclonal antibody.

Crestone’s CRS3123 Shows Superior Efficacy in Curing C. difficile Infections and Preventing Recurrence Compared to Vancomycin in Phase 2 Trial

8 months ago talkbio0Tagged Antibiotics, C. difficile, CRS3123, Effectiveness, Phase 2 clinical trial, prevention of later incidences of a disorder, vancomycin

C. difficile infections, CRS3123, Vancomycin, Phase 2 clinical trial, Antibiotic efficacy, Recurrence prevention

Lilly’s Once-Weekly Insulin Efsitora Alfa Achieves Non-Inferiority in Four Phase 3 Trials

8 months ago talkbio0Tagged Administration occupational activities, Alfa, Diabetes, efsitora, Eli, Eli Lilly, Hemoglobin A1c measurement, Insulin, insulin therapy, non-inferiority, once-weekly, Phase 3 trials

Eli Lilly, efsitora alfa, once-weekly insulin, diabetes management, Phase 3 trials, non-inferiority, A1C reduction, insulin therapy.

ImmunityBio Secures FDA Approval for ANKTIVA but Faces Financial Challenges

8 months ago talkbio0Tagged Agonist, Anktiva, Approved, Cancer Therapeutic Procedure, financial troubles, ImmunityBio, Immunotherapy, Interleukin-15, United States Food and Drug Administration

ImmunityBio, FDA approval, ANKTIVA, financial troubles, cancer treatment, IL-15 agonist immunotherapy

Eli Lilly’s Weekly Insulin Efsitora Alfa Shows Promising Results in Late-Stage Trials

8 months ago talkbio0Tagged Administration occupational activities, Alfa, Diabetes, efsitora, Eli, Eli Lilly, Insulin, insulin therapy, Phase 3 Clinical Trials, QWINT-1, QWINT-3, Weekly

Eli Lilly, weekly insulin, efsitora alfa, type 2 diabetes, Phase III trials, QWINT-1, QWINT-3, insulin therapy, diabetes management

Pfizer and Valneva Report Strong Immune Responses from Second Lyme Disease Vaccine Booster

8 months ago talkbio0Tagged Immune response, Lyme Disease, Pfizer, Phase 2 Trials, Submission, United States Food and Drug Administration, Vaccines, Valneva, VLA15

Lyme disease, vaccine, Pfizer, Valneva, VLA15, booster, immune response, Phase 2 trials, FDA submission

Enhancing Flu Vaccine Uptake in the Post-Pandemic Era: Strategies and Insights

8 months ago talkbio0Tagged Health Personnel, historical period, Post-Pandemic, public health strategies, Uptake, Urinary hesitation, Vaccination, Vaccines

flu vaccine uptake, post-pandemic era, vaccine hesitancy, public health strategies, healthcare providers, influenza vaccination

FDA Authorizes Novavax’s Updated COVID-19 Vaccine for Emergency Use

8 months ago talkbio0Tagged authorization, COVID19 (disease), Emergency Situation, JN.1, Novavax, protein-based vaccine, United States Food and Drug Administration, Vaccines, Variant

Novavax COVID-19 Vaccine, FDA Authorization, Emergency Use, Protein-Based Vaccine, JN.1 Variant

Vaxcyte Announces Positive Phase 1/2 Results for VAX-31, Advances to Phase 3

8 months ago talkbio0Tagged Bacterial Infections, development aspects, Phase 3 program, pneumococcal conjugate, Vaccines, VAX-31, Vaxcyte

Vaxcyte, VAX-31, pneumococcal conjugate vaccine, Phase 1/2 study, Phase 3 program, vaccine development, bacterial diseases